ANMAT Disqualifies Five Laboratories for Production Irregularities
The National Administration of Drugs, Food and Medical Technology (ANMAT) has officially disqualified five laboratories due to serious irregularities in their product quality. This decision underscores the importance of adhering to safety regulations and good manufacturing practices in the pharmaceutical industry.
Laboratories Affected
The companies affected by this disqualification include:
- Weltrap Laboratories SA
- Incaico Laboratory SA
- Carter Pack SRL
- Pacemaker SRL
- LADECE SA
These actions were formalized through provisions published in the Official Gazette, specifically provisions 8702/2025, 8706/2025, 8707/2025, 8708/2025, and 22/2026.
Reasons for Disqualification
The disqualification stems primarily from the absence of qualified technical directors, a crucial requirement under good manufacturing practices (GMP). The National Institute of Medicines (INAME) found that none of the first four companies had appointed qualified personnel responsible for ensuring product safety and compliance with regulatory standards.
Critical Deficiencies Identified
ANMAT and INAME emphasized that the lack of a technical director poses a critical deficiency that compromises the safety, efficacy, and quality of medicines. The inspection revealed that without adequate oversight, the potential risks to public health are significant.
Unique Case of LADECE SA
In the case of LADECE SA, the situation was deemed particularly alarming due to the potential health risks associated with its products. INAME has characterized this scenario as “critical,” referencing the risk of death or severe health implications for consumers.
LADECE SA was found manufacturing, releasing, and marketing several products, including:
- Isopropyl alcohol
- Eucalyptus essence
- Sodium borate
- Magnesium chloride
- Boric acid
- Laser paste
- Ammonium stearate ointment
These products were being processed without the necessary authorizations or registrations.
Violations and Regulatory Breaches
The inspection reports indicated that LADECE SA lacked adequate withdrawal management systems and failed to notify ANMAT of product recalls. Such lapses constitute clear violations of ANMAT Provision No. 1402/2008, which necessitates immediate communication with INAME regarding any market corrections.
The irregularities were first detected by the Pharmacy Inspection Department of the Ministry of Health in Santa Fe, through an alert that guided subsequent investigations into the lab’s practices.
Records and Authorizations Lapses
Further investigations found serious gaps in record-keeping, particularly regarding the production, processing, and marketing of key products such as isopropyl alcohol and eucalyptus essence. Many of the products lacked current authorizations, and unauthorized areas were identified for certain manufacturing processes.
Consequences and Recommendations
As a result of these findings, INAME has recommended a full prohibition on the use, marketing, and distribution of the implicated products. LADECE SA must recover the affected products and present documentation to ensure compliance with both market regulatory demands and public safety protocols.
Regulatory Framework Importance
This incident serves as a stark reminder of the stringent regulatory framework governing drug production. All activities related to pharmaceuticals and chemicals must be appropriately authorized and monitored to ensure public health and safety. It highlights the necessity for companies to operate under the guidance of skilled professionals, such as qualified pharmacists or chemists, to maintain high standards of safety and efficacy in medicine production.
Conclusion
The disqualification by ANMAT not only highlights specific failures within these laboratories but also reinforces the crucial role regulatory bodies play in safeguarding public health. The pharmaceutical industry must prioritize adherence to regulations and quality standards to avoid such repercussions and protect consumer safety effectively.